Sugi Predict

Sugi Predict / Compounds / SCHEMBL2729001

SCHEMBL2729001

SCHEMBL2729001

COC(=O)c1sc(Br)cc1CBr

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 1/20 0.43
▸ MAPT P10636 4/20 0.40
▸ HSD17B10 Q99714 3/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ RAF1 P04049 1/20 0.40
▸ L3MBTL1 Q9Y468 3/20 0.38
▸ PPARG P37231 1/20 0.38
▸ NCOA1 Q15788 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ NCOA3 Q9Y6Q9 1/20 0.38
▸ KDM4E B2RXH2 4/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ CASP3 P42574 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SENP8 Q96LD8 1/20 0.37
▸ SENP7 Q9BQF6 1/20 0.37
▸ SENP6 Q9GZR1 1/20 0.37
▸ IKBKB O14920 1/20 0.37
▸ ALDH1A1 P00352 5/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29122566 0.88 HSD17B10 (0.42) GSK3BMAPTHSD17B10KMT2ATSHR
SCHEMBL31222852 0.85 L3MBTL1 (0.46) GSK3BMAPTHSD17B10KMT2ATSHR
SCHEMBL14390861 0.83 RAF1 (0.43) MAPTHSD17B10KMT2ATSHRRAF1
SCHEMBL20263529 0.82 GSK3B (0.40) GSK3BMAPTKMT2AL3MBTL1KDM4E
SCHEMBL21152318 0.81 IKBKB (0.42) MAPTHSD17B10KMT2ATSHRRAF1
SCHEMBL13545972 0.81 RAF1 (0.39) MAPTHSD17B10KMT2ATSHRRAF1
SCHEMBL161941 0.79 L3MBTL1 (0.60) MAPTRAF1L3MBTL1PKM
SCHEMBL102283 0.79 KDM4E (0.53) MAPTHSD17B10KMT2ATSHRL3MBTL1
SCHEMBL319034 0.78 GSK3B (0.53) GSK3BMAPTHSD17B10KMT2ATSHR
SCHEMBL2170599 0.78 GSK3B (0.48) GSK3BNPSR1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676476-A1 INHIBITORS OF TDP-43 AND TAU AGGREGATION Aquinnah Pharmaceuticals, Inc. (US) 2026-01-14 — — EP disclosed
US-20250304563-A1 ACTIVATORS OF EFFECTOR T CELLS ORUM THERAPEUTICS, INC. (KR) 2025-10-02 — — US disclosed
EP-4490152-A1 ACTIVATORS OF EFFECTOR T CELLS Orum Therapeutics Inc. (KR) 2025-01-15 — — EP disclosed
WO-2024187126-A1 INHIBITORS OF TDP-43 AND TAU AGGREGATION AQUINNAH PHARMACEUTICALS, INC. (US) 2024-09-12 — — WO disclosed
CN-112601751-B Fused thiophene compounds 拜欧斯瑞克斯公司 2024-04-02 — — CN disclosed
WO-2023170608-A1 ACTIVATORS OF EFFECTOR T CELLS ORUM THERAPEUTICS, INC. (KR) 2023-09-14 — — WO disclosed
US-20230212171-A1 ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. 2023-07-06 — — US disclosed
US-11345714-B2 Compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2022-05-31 — — US disclosed
US-20220088025-A1 FUSED THIOPHENE COMPOUNDS BIOTHERYX, INC. 2022-03-24 — — US disclosed
WO-2021252661-A1 ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-12-16 — — WO disclosed
WO-2018118947-A1 THIENOPYRROLE DERIVATIVES FOR USE IN TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. (US) 2018-06-28 — — WO disclosed
US-20180170948-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF Bio TheryX, Inc. 2018-06-21 — — US disclosed
CN-107922433-A Antibacterial Cyclic Pyrrolidin-2-one Derivatives 爱杜西亚药品有限公司 2018-04-17 — — CN disclosed
WO-2017036968-A1 ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2017-03-09 — — WO disclosed
US-9056859-B2 Inhibitors of the renal outer medullary potassium channel MERCK SHARP & DOHME CORP. (US) 2015-06-16 — — US disclosed
EP-2632464-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME (US) 2015-04-29 — — EP disclosed
EP-2632464-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL Merck Sharp & Dohme Corp. (US) 2013-09-04 — — EP disclosed
US-20130217680-A1 Inhibitors of the Renal Outer Medullary Potassium Channel MERCK SHARP & DOHME LLC 2013-08-22 — — US disclosed
WO-2012058134-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2012-05-03 — — WO disclosed
US-20100009973-A1 Integrase Inhibitors 3 AVEXA LIMITED (AU) 2010-01-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11345714-B2 Compounds targeting proteins, compositions, methods, and uses thereof CKS1B, IKZF3, EPAS1 GSK3B 121/4885MAPT 774/4885HSD17B10 4503/4885
US-20250304563-A1 ACTIVATORS OF EFFECTOR T CELLS CBLB, CBL, CBLC GSK3B 586/4885MAPT 3494/4885HSD17B10 3919/4885
US-20180170948-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF CKS1B, IKZF3, EPAS1 GSK3B 121/4885MAPT 774/4885HSD17B10 4503/4885
US-20220088025-A1 FUSED THIOPHENE COMPOUNDS SSB, ICAM1, VCAM1 GSK3B 3565/4885MAPT 853/4885HSD17B10 3881/4885
US-20130217680-A1 Inhibitors of the Renal Outer Medullary Potassium Channel KCNJ11, KCNJ1, KCNJ2 GSK3B 2063/4885MAPT 4110/4885HSD17B10 3153/4885
US-20230212171-A1 ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF EGFR, ERBB2, ERBB3 GSK3B 242/4885MAPT 3718/4885HSD17B10 4296/4885
US-20100009973-A1 Integrase Inhibitors 3 TYMP, IMPDH1, IMPDH2 GSK3B 49/4885MAPT 3484/4885HSD17B10 999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.